Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy, Tissue Engineered), By Phase, By Indication, By Region, And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 2 Business Days
Advanced Therapy Medicinal Products CDMO Market Growth & Trends
The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.8% from 2023 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.
Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.
Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.
On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.
Advanced Therapy Medicinal Products CDMO Market Report Highlights
Advanced Therapy Medicinal Products CDMO Market Growth & Trends
The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.8% from 2023 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.
Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.
Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.
On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.
Advanced Therapy Medicinal Products CDMO Market Report Highlights
- By product, gene therapy accounted for a major share of market space due to increasing clinical trials for gene therapies. Moreover, collaborative efforts for the development of novel gene therapies and the resultant expansion in gene therapy applications are factors expected to drive the volume of manufacturing
- Cell therapy is expected to account for a significant market share in the coming years. A rise in research interests and the adoption of advanced cell therapies are attracting increased investments. The segment is being driven by CDMOs attracting investments to keep up with growing commercial markets and support their growth and diversification prospects
- By phase, the phase I segment dominated the market revenue share in 2022. This is attributed to the growing number of human trials for advanced therapies and rising R&D activities
- By indication, the oncology segment held a major share of the market in 2022 due to the increasing number of cancer patients and increasing cell and gene therapy research related to cancer. Moreover, technological advancements, such as the development of cancer vaccines, are expected to further support segment growth
- North America dominated the global market in 2022, owing to increasing healthcare expenditure and the presence of key players. Companies such as Novartis AG, Sanofi, Johnson & Johnson Services, Inc., and Viatris are positively influencing market growth
- For instance, in June 2022, Novartis AG launched Dimethyl fumarate HEXAL for the treatment of patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in Germany. This strategic launch was aimed at commercializing Hexal in Germany
- The Asia Pacific region is expected to expand considerably in the future. China is one of the major markets in the region. The market growth can be attributed to increasing government investments and reforms in policies related to the manufacturing of pharmaceutical products. China ranked second in the world for cell & gene therapy development with more than 1,000 clinical trials conducted in the country
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective
1.8.2 Objective
1.8.3 Objective
1.8.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
CHAPTER 3 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Rising number of clinical trials for ATMPs
3.1.1.2 Increasing outsourcing activities
3.1.1.3 Growing awareness of the treatment
3.1.2 Market Restraint Analysis
3.1.2.1 Stringent regulatory approvals
3.1.2.2 High cost of outsourcing
3.2 Business Environment Analysis Tools
3.2.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.2.2 Porter’s Five Forces Analysis
CHAPTER 4 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET - SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD BILLION)
4.1 Advanced Therapy Medicinal Products CDMO market: Product Movement Analysis
4.2 Gene Therapy
4.2.1 Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market estimates and forecast, 2018 - 2030 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market estimates and forecast, 2018 - 2030 (USD Billion)
4.5 Others
4.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 5 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET - SEGMENT ANALYSIS, BY PHASE, 2018 - 2030 (USD BILLION)
5.1 Advanced Therapy Medicinal Products CDMO market: Phase movement analysis
5.2 Phase
5.2.1 Phase 1 market estimates and forecast, 2018 - 2030 (USD Billion)
5.3 Phase
5.3.1 Phase 2 market estimates and forecast, 2018 - 2030 (USD Billion)
5.4 Phase
5.4.1 Phase 3 market estimates and forecast, 2018 - 2030 (USD Billion)
5.5 Phase
5.5.1 Phase 4 market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 6 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET - SEGMENT ANALYSIS, BY INDICATION, 2018 - 2030 (USD BILLION)
6.1 Advanced therapy medicinal products CDMO market: Indication movement analysis
6.2 Oncology
6.2.1 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market estimates and forecast, 2018 - 2030 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market estimates and forecast, 2018 - 2030 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market estimates and forecast, 2018 - 2030 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market estimates and forecast, 2018 - 2030 (USD Billion)
6.9 Immunology & Inflammation
6.9.1 Immunology & inflammation market estimates and forecast, 2018 - 2030 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market estimates and forecast, 2018 - 2030 (USD Billion)
6.11 Hematology
6.11.1 Hematology market estimates and forecast, 2018 - 2030 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market estimates and forecast, 2018 - 2030 (USD Billion)
6.13 Others
6.13.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET: REGIONAL MARKET ANALYSIS, 2018 - 2030 (USD BILLION)
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Advanced therapy Medicinal products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.10 Rest of Europe Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Advanced Therapy Medicinal Prodcut CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.5 South Korea
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 South Korea Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.6 Australia
7.3.6.1 Target Disease Prevalence
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.6.5 Austrlia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.7 Thailand
7.3.7.1 Target Disease Prevalence
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.7.5 Thailand Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.8 Rest of Asia Pacific Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.2 KEY Regional DYNAMICS
7.4.2.1 Latin America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3 Brazil
7.4.3.1 Target Disease Prevalence
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4 Mexico
7.4.4.1 Target Disease Prevalence
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.4.5 Mexico Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.5 Argentina
7.4.5.1 Target Disease Prevalence
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.5.5 Argentina Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.6 Colombia
7.4.6.1 Target Disease Prevalence
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.6.5 Colombia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.7 Chile
7.4.7.1 Target Disease Prevalence
7.4.7.2 Competitive Scenario
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.4.7.5 Chile Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.8 Rest of LATAM Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.2 KEY regional DYNAMICS
7.5.2.1 Middle East & Africa advanced therapy medicinal products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3 South Africa
7.5.3.1 Target Disease Prevalence
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Reimbursement Scenario
7.5.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4 Saudi Arabia
7.5.4.1 Target Disease Prevalence
7.5.4.2 Competitive Scenario
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.5.4.5 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5 UAE
7.5.5.1 Target Disease Prevalence
7.5.5.2 Competitive Scenario
7.5.5.3 Regulatory Framework
7.5.5.4 Reimbursement Scenario
7.5.5.5 UAE Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6 Israel
7.5.6.1 Target Disease Prevalence
7.5.6.2 Competitive Scenario
7.5.6.3 Regulatory Framework
7.5.6.4 Reimbursement Scenario
7.5.6.5 Israel Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7 Egypt
7.5.7.1 Target Disease Prevalence
7.5.7.2 Competitive Scenario
7.5.7.3 Regulatory Framework
7.5.7.4 Reimbursement Scenario
7.5.7.5 Egypt Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8 Kuwait
7.5.8.1 Target Disease Prevalence
7.5.8.2 Competitive Scenario
7.5.8.3 Regulatory Framework
7.5.8.4 Reimbursement Scenario
7.5.8.5 Kuwait Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9 Rest of MEA Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 8 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET: COMPETITIVE ANALYSIS
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 CELONIC Group
8.2.1.1 Company Overview
8.2.1.2 Product Benchmarking
8.2.1.3 Strategic Initiatives
8.2.2 Bio Elpida
8.2.2.1 Company Overview
8.2.2.2 Product Benchmarking
8.2.2.3 Strategic Initiatives
8.2.3 Rentschler Biopharma SE
8.2.3.1 Company Overview
8.2.3.2 Product Benchmarking
8.2.3.3 Strategic Initiatives
8.2.4 AGC Biologics
8.2.4.1 Company Overview
8.2.4.2 Product Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Catalent, Inc.
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.6 Lonza
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.7 WuXi Advanced Therapies
8.2.7.1 Company Overview
8.2.7.2 Product Benchmarking
8.2.7.3 Strategic Initiatives
8.2.8 Minaris Regenerative Medicine
8.2.8.1 Company Overview
8.2.8.2 Product Benchmarking
8.2.8.3 Strategic Initiatives
8.2.9 Patheon, Inc.
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.10 Cell and Gene Therapy Catapult (CGT Catapult)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective
1.8.2 Objective
1.8.3 Objective
1.8.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
CHAPTER 3 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Rising number of clinical trials for ATMPs
3.1.1.2 Increasing outsourcing activities
3.1.1.3 Growing awareness of the treatment
3.1.2 Market Restraint Analysis
3.1.2.1 Stringent regulatory approvals
3.1.2.2 High cost of outsourcing
3.2 Business Environment Analysis Tools
3.2.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.2.2 Porter’s Five Forces Analysis
CHAPTER 4 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET - SEGMENT ANALYSIS, BY PRODUCT, 2018 - 2030 (USD BILLION)
4.1 Advanced Therapy Medicinal Products CDMO market: Product Movement Analysis
4.2 Gene Therapy
4.2.1 Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market estimates and forecast, 2018 - 2030 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market estimates and forecast, 2018 - 2030 (USD Billion)
4.5 Others
4.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 5 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET - SEGMENT ANALYSIS, BY PHASE, 2018 - 2030 (USD BILLION)
5.1 Advanced Therapy Medicinal Products CDMO market: Phase movement analysis
5.2 Phase
5.2.1 Phase 1 market estimates and forecast, 2018 - 2030 (USD Billion)
5.3 Phase
5.3.1 Phase 2 market estimates and forecast, 2018 - 2030 (USD Billion)
5.4 Phase
5.4.1 Phase 3 market estimates and forecast, 2018 - 2030 (USD Billion)
5.5 Phase
5.5.1 Phase 4 market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 6 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET - SEGMENT ANALYSIS, BY INDICATION, 2018 - 2030 (USD BILLION)
6.1 Advanced therapy medicinal products CDMO market: Indication movement analysis
6.2 Oncology
6.2.1 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market estimates and forecast, 2018 - 2030 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market estimates and forecast, 2018 - 2030 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market estimates and forecast, 2018 - 2030 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market estimates and forecast, 2018 - 2030 (USD Billion)
6.9 Immunology & Inflammation
6.9.1 Immunology & inflammation market estimates and forecast, 2018 - 2030 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market estimates and forecast, 2018 - 2030 (USD Billion)
6.11 Hematology
6.11.1 Hematology market estimates and forecast, 2018 - 2030 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market estimates and forecast, 2018 - 2030 (USD Billion)
6.13 Others
6.13.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
CHAPTER 7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET: REGIONAL MARKET ANALYSIS, 2018 - 2030 (USD BILLION)
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Advanced therapy Medicinal products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.2.10 Rest of Europe Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Advanced Therapy Medicinal Prodcut CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.5 South Korea
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 South Korea Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.6 Australia
7.3.6.1 Target Disease Prevalence
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.6.5 Austrlia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.7 Thailand
7.3.7.1 Target Disease Prevalence
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.7.5 Thailand Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3.8 Rest of Asia Pacific Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.2 KEY Regional DYNAMICS
7.4.2.1 Latin America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3 Brazil
7.4.3.1 Target Disease Prevalence
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4 Mexico
7.4.4.1 Target Disease Prevalence
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.4.5 Mexico Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.5 Argentina
7.4.5.1 Target Disease Prevalence
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.5.5 Argentina Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.6 Colombia
7.4.6.1 Target Disease Prevalence
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.6.5 Colombia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.7 Chile
7.4.7.1 Target Disease Prevalence
7.4.7.2 Competitive Scenario
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.4.7.5 Chile Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.8 Rest of LATAM Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.2 KEY regional DYNAMICS
7.5.2.1 Middle East & Africa advanced therapy medicinal products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3 South Africa
7.5.3.1 Target Disease Prevalence
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Reimbursement Scenario
7.5.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4 Saudi Arabia
7.5.4.1 Target Disease Prevalence
7.5.4.2 Competitive Scenario
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.5.4.5 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5 UAE
7.5.5.1 Target Disease Prevalence
7.5.5.2 Competitive Scenario
7.5.5.3 Regulatory Framework
7.5.5.4 Reimbursement Scenario
7.5.5.5 UAE Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6 Israel
7.5.6.1 Target Disease Prevalence
7.5.6.2 Competitive Scenario
7.5.6.3 Regulatory Framework
7.5.6.4 Reimbursement Scenario
7.5.6.5 Israel Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7 Egypt
7.5.7.1 Target Disease Prevalence
7.5.7.2 Competitive Scenario
7.5.7.3 Regulatory Framework
7.5.7.4 Reimbursement Scenario
7.5.7.5 Egypt Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8 Kuwait
7.5.8.1 Target Disease Prevalence
7.5.8.2 Competitive Scenario
7.5.8.3 Regulatory Framework
7.5.8.4 Reimbursement Scenario
7.5.8.5 Kuwait Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9 Rest of MEA Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 8 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET: COMPETITIVE ANALYSIS
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 CELONIC Group
8.2.1.1 Company Overview
8.2.1.2 Product Benchmarking
8.2.1.3 Strategic Initiatives
8.2.2 Bio Elpida
8.2.2.1 Company Overview
8.2.2.2 Product Benchmarking
8.2.2.3 Strategic Initiatives
8.2.3 Rentschler Biopharma SE
8.2.3.1 Company Overview
8.2.3.2 Product Benchmarking
8.2.3.3 Strategic Initiatives
8.2.4 AGC Biologics
8.2.4.1 Company Overview
8.2.4.2 Product Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Catalent, Inc.
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.6 Lonza
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.7 WuXi Advanced Therapies
8.2.7.1 Company Overview
8.2.7.2 Product Benchmarking
8.2.7.3 Strategic Initiatives
8.2.8 Minaris Regenerative Medicine
8.2.8.1 Company Overview
8.2.8.2 Product Benchmarking
8.2.8.3 Strategic Initiatives
8.2.9 Patheon, Inc.
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.10 Cell and Gene Therapy Catapult (CGT Catapult)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 4 Global Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 5 Global Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 6 Global Advanced Therapy Medicinal Products CDMO Market by Region, 2018 - 2030 (USD Billion)
Table 7 North America Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 8 North America Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 9 North America Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 10 North America Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 11 U.S. Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 12 U.S. Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 13 U.S. Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 14 Canada Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 15 Canada Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 16 Canada Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 17 Europe Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 18 Europe Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 19 Europe Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 20 Europe Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 21 Germany Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 22 Germany Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 23 Germany Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 24 UK Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 25 UK Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 26 UK Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 27 France Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 28 France Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 29 France Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 30 Italy Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 31 Italy Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 32 Italy Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 33 Spain Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 34 Spain Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 35 Spain Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 36 Denmark Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 37 Denmark Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 38 Denmark Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 39 Sweden Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 40 Sweden Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 41 Sweden Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 42 Norway Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 43 Norway Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 44 Norway Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 45 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 46 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 47 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 48 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 49 China Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 50 China Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 51 China Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 52 Japan Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 53 Japan Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 54 Japan Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 55 India Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 56 India Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 57 India Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 58 South Korea Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 59 South Korea Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 60 South Korea Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 61 Australia Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 62 Australia Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 63 Australia Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 64 Thailand Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 65 Thailand Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 66 Thailand Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 67 Latin America Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 68 Latin America Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 69 Latin America Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 70 Latin America Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 71 Brazil Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 72 Brazil Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 73 Brazil Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 74 Mexico Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 75 Mexico Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 76 Mexico Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 77 Argentina Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 78 Argentina Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 79 Argentina Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 80 Colombia Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 81 Colombia Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 82 Colombia Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 83 Chile Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 84 Chile Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 85 Chile Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 86 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 87 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 88 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 89 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 90 South Africa Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 91 South Africa Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 92 South Africa Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 93 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 94 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 95 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 96 UAE Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 97 UAE Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 98 UAE Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 99 Israel Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 100 Israel Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 101 Israel Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 102 Egypt Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 103 Egypt Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 104 Egypt Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 105 Kuwait Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 106 Kuwait Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 107 Kuwait Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 4 Global Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 5 Global Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 6 Global Advanced Therapy Medicinal Products CDMO Market by Region, 2018 - 2030 (USD Billion)
Table 7 North America Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 8 North America Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 9 North America Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 10 North America Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 11 U.S. Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 12 U.S. Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 13 U.S. Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 14 Canada Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 15 Canada Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 16 Canada Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 17 Europe Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 18 Europe Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 19 Europe Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 20 Europe Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 21 Germany Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 22 Germany Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 23 Germany Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 24 UK Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 25 UK Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 26 UK Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 27 France Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 28 France Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 29 France Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 30 Italy Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 31 Italy Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 32 Italy Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 33 Spain Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 34 Spain Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 35 Spain Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 36 Denmark Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 37 Denmark Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 38 Denmark Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 39 Sweden Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 40 Sweden Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 41 Sweden Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 42 Norway Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 43 Norway Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 44 Norway Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 45 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 46 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 47 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 48 Asia Pacific Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 49 China Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 50 China Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 51 China Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 52 Japan Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 53 Japan Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 54 Japan Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 55 India Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 56 India Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 57 India Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 58 South Korea Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 59 South Korea Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 60 South Korea Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 61 Australia Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 62 Australia Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 63 Australia Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 64 Thailand Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 65 Thailand Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 66 Thailand Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 67 Latin America Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 68 Latin America Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 69 Latin America Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 70 Latin America Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 71 Brazil Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 72 Brazil Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 73 Brazil Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 74 Mexico Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 75 Mexico Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 76 Mexico Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 77 Argentina Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 78 Argentina Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 79 Argentina Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 80 Colombia Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 81 Colombia Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 82 Colombia Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 83 Chile Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 84 Chile Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 85 Chile Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 86 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Country, 2018 - 2030 (USD Billion)
Table 87 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 88 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 89 Middle East & Africa Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 90 South Africa Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 91 South Africa Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 92 South Africa Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 93 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 94 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 95 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 96 UAE Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 97 UAE Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 98 UAE Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 99 Israel Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 100 Israel Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 101 Israel Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 102 Egypt Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 103 Egypt Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 104 Egypt Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
Table 105 Kuwait Advanced Therapy Medicinal Products CDMO Market by Product, 2018 - 2030 (USD Billion)
Table 106 Kuwait Advanced Therapy Medicinal Products CDMO Market by Phase, 2018 - 2030 (USD Billion)
Table 107 Kuwait Advanced Therapy Medicinal Products CDMO Market by Indication, 2018 - 2030 (USD Billion)
LIST OF FIGURES
Fig. 1 Advanced therapy medicinal products CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Advanced therapy medicinal products CDMO market driver impact
Fig. 10 Pipeline of gene, cell, and RNA therapies as of Q1 2022
Fig. 11 CAR-T cell therapy pipeline distribution as per indication in Q4 2021
Fig. 12 Gene therapies in clinical trials in the Q1 2022 globally
Fig. 13 Advanced therapy medicinal products CDMO market restraint impact
Fig. 14 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 15 Porter’s Five Forces Analysis
Fig. 16 Advanced therapy medicinal products CDMO market: Product outlook and key takeaways
Fig. 17 Advanced therapy medicinal products CDMO market: Product movement analysis
Fig. 18 Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 19 Cell therapy market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 20 Tissue engineered market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 22 Advanced therapy medicinal products CDMO market: Phase outlook and key takeaways
Fig. 23 Advanced therapy medicinal products CDMO market: Phase movement analysis
Fig. 24 Phase 1 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 25 Phase 2 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 26 Phase 3 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 27 Phase 4 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 28 Advanced therapy medicinal products CDMO market: Indication outlook and key takeaways
Fig. 29 Advanced therapy medicinal products CDMO market: Indication movement analysis
Fig. 30 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 31 Cardiology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 32 Central nervous system market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 33 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 34 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 35 Dermatology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 36 Endocrine, metabolic, genetic market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 37 Immunology & inflammation market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 38 Ophthalmology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 39 Hematology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 40 Gastroenterology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America: SWOT analysis
Fig. 44 North America advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 47 U.S. advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 50 Canada advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 Europe: SWOT analysis
Fig. 52 Europe advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Key country dynamics
Fig. 54 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 55 Germany advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 Key country dynamics
Fig. 57 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 58 UK advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 59 Key country dynamics
Fig. 60 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 61 France advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 62 Key country dynamics
Fig. 63 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 64 Italy advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 65 Key country dynamics
Fig. 66 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 67 Spain advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 68 Key country dynamics
Fig. 69 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 70 Denmark advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 71 Key country dynamics
Fig. 72 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 73 Sweden advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 74 Key country dynamics
Fig. 75 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 76 Norway advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 77 Rest of Europe advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 78 Asia Pacific: SWOT analysis
Fig. 79 Asia Pacific region dynamics
Fig. 80 Asia Pacific advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 81 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 82 Japan advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 83 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 84 China advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 85 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 86 India advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 87 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 88 South Korea advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 89 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 90 Australia advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 91 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 92 Thailand advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 93 Rest of Asia Pacific advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 94 Latin America: SWOT analysis
Fig. 95 Latin America regional dynamics
Fig. 96 Latin America advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 97 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 98 Brazil advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 99 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 100 Mexico advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 101 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 102 Argentina advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 103 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 104 Colombia advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 105 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 106 Chile advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 107 Rest of LATAM advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 108 MEA: SWOT analysis
Fig. 109 MEA-regional dynamics
Fig. 110 Middle East & Africa advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 111 Target disease prevalence (Patient Volume) ('000) 2018 - 2030
Fig. 112 Brazil advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 113 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 114 Saudi Arabia advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 115 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 116 UAE advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 117 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 118 Israel advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 119 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 120 Egypt advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 121 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 122 Kuwait advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 123 Rest of MEA advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 124 Strategic framework
Fig. 1 Advanced therapy medicinal products CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Advanced therapy medicinal products CDMO market driver impact
Fig. 10 Pipeline of gene, cell, and RNA therapies as of Q1 2022
Fig. 11 CAR-T cell therapy pipeline distribution as per indication in Q4 2021
Fig. 12 Gene therapies in clinical trials in the Q1 2022 globally
Fig. 13 Advanced therapy medicinal products CDMO market restraint impact
Fig. 14 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 15 Porter’s Five Forces Analysis
Fig. 16 Advanced therapy medicinal products CDMO market: Product outlook and key takeaways
Fig. 17 Advanced therapy medicinal products CDMO market: Product movement analysis
Fig. 18 Gene therapy market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 19 Cell therapy market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 20 Tissue engineered market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 22 Advanced therapy medicinal products CDMO market: Phase outlook and key takeaways
Fig. 23 Advanced therapy medicinal products CDMO market: Phase movement analysis
Fig. 24 Phase 1 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 25 Phase 2 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 26 Phase 3 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 27 Phase 4 market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 28 Advanced therapy medicinal products CDMO market: Indication outlook and key takeaways
Fig. 29 Advanced therapy medicinal products CDMO market: Indication movement analysis
Fig. 30 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 31 Cardiology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 32 Central nervous system market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 33 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 34 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 35 Dermatology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 36 Endocrine, metabolic, genetic market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 37 Immunology & inflammation market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 38 Ophthalmology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 39 Hematology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 40 Gastroenterology market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Billion)
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America: SWOT analysis
Fig. 44 North America advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 47 U.S. advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 50 Canada advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 Europe: SWOT analysis
Fig. 52 Europe advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Key country dynamics
Fig. 54 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 55 Germany advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 Key country dynamics
Fig. 57 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 58 UK advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 59 Key country dynamics
Fig. 60 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 61 France advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 62 Key country dynamics
Fig. 63 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 64 Italy advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 65 Key country dynamics
Fig. 66 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 67 Spain advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 68 Key country dynamics
Fig. 69 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 70 Denmark advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 71 Key country dynamics
Fig. 72 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 73 Sweden advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 74 Key country dynamics
Fig. 75 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 76 Norway advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 77 Rest of Europe advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 78 Asia Pacific: SWOT analysis
Fig. 79 Asia Pacific region dynamics
Fig. 80 Asia Pacific advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 81 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 82 Japan advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 83 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 84 China advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 85 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 86 India advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 87 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 88 South Korea advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 89 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 90 Australia advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 91 Target disease prevalence (patient volume) ('000) 2018 - 2030
Fig. 92 Thailand advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 93 Rest of Asia Pacific advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 94 Latin America: SWOT analysis
Fig. 95 Latin America regional dynamics
Fig. 96 Latin America advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 97 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 98 Brazil advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 99 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 100 Mexico advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 101 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 102 Argentina advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 103 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 104 Colombia advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 105 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 106 Chile advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 107 Rest of LATAM advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 108 MEA: SWOT analysis
Fig. 109 MEA-regional dynamics
Fig. 110 Middle East & Africa advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 111 Target disease prevalence (Patient Volume) ('000) 2018 - 2030
Fig. 112 Brazil advanced therapy medicinal products CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 113 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 114 Saudi Arabia advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 115 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 116 UAE advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 117 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 118 Israel advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 119 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 120 Egypt advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 121 Target disease prevalence (Patient volume) ('000) 2018 - 2030
Fig. 122 Kuwait advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 123 Rest of MEA advanced therapy medicinal product CDMO market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 124 Strategic framework
